NCT06543641Completed
Evaluation of Long Coronary Artery Stents With Third-generation Dual-source Computed Tomography Angiography
Source: ClinicalTrials.gov · Last updated 9 Aug 2024
Brief summary (registry, in English)
The goal of this clinical trial is to assess third-generation dual-source coronary computed tomography angiography (CCTA) performance in the evaluation of long coronary stents in patients with coronary artery chronic total occlusions. The main questions it aims to answer are: * Can patency of long coronary artery stents be assessed with third generation CCTA? * What are the factors affecting the assessability? * What is the radiation exposure of third generation CCTA?
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 45 (actual)
- First submitted
- 25 Jul 2024
- Start date
- 16 Jan 2023
- Primary completion date
- 10 Nov 2023
- Lead sponsor
- Lauri Mansikkaniemi
- Diseases
- Coronary artery disease
- NCT number
- NCT06543641
What you commit to
- Study type: Interventional
- Participants enrolled: 45
- From 16 Jan 2023 to the primary completion date, 10 Nov 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Active alcohol or drug abuse
- ICA or CCTA less than six months prior to the study date
Other illness
- Malignancy with poor prognosis or ongoing diagnostics
- Significant psychiatric disorder
- Memory disorder or other cognitive impairment
Other
- Significantly impaired performance in daily activities
- Primary procedure in-stent CTO PCI
- Target vessel revascularisation or CABG after the primary - procedure
- Glomerular filtration rate ≤40 ml/min
Who the study is looking for
- Surviving patients with a CTO PCI minimum of four years prior to the study date
- Successful CTO PCI with a drug-eluting stent
- Primary procedure minimum of four years prior to study date
- CTO stent length ≥ 38 mm in right coronary artery (RCA) and left anterior descending (LAD) coronary artery
- CTO stent length ≥ 30 mm in left circumflex coronary artery (LCX). The definition is clinical.
- Age at primary procedure ≤ 75 years
- Communication in English, Finnish or Swedish
Age in the registry: - to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Helsinki University Central Hospital Coordinator of this site? Confirm its status | Helsinki | Finland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.